EGFR and non-small cell lung carcinoma: While osimertinib has proven effective for most patients with EGFR-mutated NSCLC, osimertinib-related HF remains a significant concern and might be more prevalent in real-world settings due to the frailer, older patient population and particularly for those at higher risk.